Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Vactosertib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedPacto
  • Most Recent Events

    • 28 Oct 2018 Status changed from planning to not yet recruiting.
    • 01 Aug 2018 New trial record
    • 24 Jul 2018 According to a MedPacto media release, the company will conduct the study in several sites in South Korea, including Asan Medical Center, National Cancer Center and Samsung Medical Center. The trial is expected to be initiated the second half of 2018 and completed within two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top